(R)-9-[(2-methylphosphonomethoxy)propyl]adenine | 1619914-53-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (R)-9-[(2-methylphosphonomethoxy)propyl]adenine
• 英文别名: [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-methylphosphinic acid
• CAS: 1619914-53-2
• 化学式: C₁₀H₁₆N₅O₃P
• 分子量: 285.242
• InChiKey: VUOMMTXOCLWPLA-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphinic acid 、 碘甲烷 在 N,O-双三甲硅基乙酰胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以57%的产率得到(R)-9-[(2-methylphosphonomethoxy)propyl]adenine
  参考文献：
  名称：

  (R)-9-[2-(Hydroxyphosphinylmethoxy)propyl]adenine as the precursor molecule for antivirals

  摘要：

  The biological importance and practical significance of phosphonates have been a major driving force for antiviral research in the past two decades. We describe in this Letter the potential of the H-phosphinate derivative (R)-9-[2-(hydroxyphosphinylmethoxy)propyl]adenine as the versatile synthetic intermediate in the preparation of N-alkylphosphonamidate and alkylphosphonate series. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2014.05.061

文献信息

• NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20150315221A1

  公开（公告）日：2015-11-05

  The present invention relates to disulfide masked prodrug compounds, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics.

  本发明涉及一种二硫化物掩蔽的前药化合物、组合物和方法，这些化合物、组合物和方法可通过还原剂如谷胱甘肽进行生物活化。这种基于二硫化物的化合物、组合物和方法可以用于提供新型前药，例如用作治疗药物。
• Methods of Treating Orthopox Virus Infections and Associated Diseases
  申请人：Lanier Ernest R.

  公开号：US20110263536A1

  公开（公告）日：2011-10-27

  The present invention provides methods of treating diseases associated with at least one virus. The methods include administering a compound described in the invention in a therapeutically effective amount. According to some aspects of the present invention, the methods provide treatment of an orthopox virus infection or a disease related to orthopox virus.
• "Methods of Reducing Nephrotoxicity in Subjects Administered Nucleoside Phosphonates"
  申请人：Painter George R.

  公开号：US20120010170A1

  公开（公告）日：2012-01-12

  A conjugate compound comprising an acyclic nucleoside phosphonate covalently coupled to a lipid for the therapeutic and/or prophylactic treatment of viral infection in an immunodeficient subject is described, along with compositions and methods of using the same. A preferred conugate compound is CMX001, having formula (I) or a pharmaceutically acceptable salt thereof.
• Composition and Methods of Treating Viral Infections and Viral Induced Tumors
  申请人：Lanier Ernest Randall

  公开号：US20120164104A1

  公开（公告）日：2012-06-28

  The present invention provides methods of treating viral induced tumor or viral infections, including administering a compound described in the invention in a therapeutically effective amount. According to some aspect of the present invention, the methods may further comprise at least one immunosuppressant agent to treat viral infection and/or viral induced tumor to a subject in need of immunosuppressant agents.
• Compounds, Compositions and Methods for Treating Ocular Conditions
  申请人：Painter George R.

  公开号：US20120165295A1

  公开（公告）日：2012-06-28

  The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered.